Digitalis Ventures
Venture capitalNew York · Seed–Late Stage · 15 people tracked
Also known as DIGITALIS VENTURES, LLC
Investment thesis
Digitalis Ventures focuses on solutions to unmet needs in biomedicine and health. On the human health side, it backs biotechnology companies leveraging breakthrough science, as well as companies building novel technology-enabled solutions that improve access to care and health outcomes while lowering costs for individuals and the broader healthcare system. Through its Companion Funds, the firm also invests in companies applying science, technology, and design to improve animal health. Digitalis emphasizes a multidisciplinary team approach to solving complex problems and shares its investment thinking publicly through the Digitalis Notebook, alongside its related efforts at Digitalis Commons and Digitalis Labs.
Source: firm website, verified Aug 25, 2026.
Team · 15 people
from the firm's website & public directories
Founder mafia
2 people who came through Digitalis Ventures went on to found or lead other companies.
What they invest in
from 45 of 56 portfolio companiesBiotech ×32Healthtech ×28Deep Tech ×12Digital Health ×9Medical Devices ×9AI & Machine Learning ×8Fintech ×4Consumer ×3
HQs:United States×33Australia×1Canada×1Germany×1United Kingdom×1
Who they back
founder profiles across 10 portfolio companiesFounding team size:solo founder×62 founders×23 founders×2
Investments · 56 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 32024 · 32021 · 22017 · 12016 · 12015 · 114 dated
Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway.
BiotechHealthtechAustin, US
Anand Parikh(Executive Officer, Director, Promoter)Oliver Maddocks(Executive Officer, Director)
BoardAlex Morgan(Director)inJayson Dallas(Director)Robert Gould(Director)Stephen Hahn(Director)
Co-investorsAble PartnersAtacama VenturesCota CapitalFuture VenturesiSelect FundS2G Investments+4 more
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Co-founder)Alfica SehgalOMMER CHOHAN(Executive Officer)JAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)William Ho
Co-investorsAtlas VentureThe Column GroupDroia VenturesYK Bioventures
Gallant develops regenerative medicine therapies for veterinary care, bringing treatments from laboratory research into clinical practice for pets.
BiotechHealthtechMedical DevicesSan Diego, US
Aaron Hirschhorn(Executive Officer, Director)Linda Black(Chief Executive Officer, Chief Financial Officer & Secretary)Davis Brimer(Executive Officer, Director)
BoardTeymour Boutros-Ghali(Director)inValentine Williams(DVM, MS, Diplomate ACVS)Aaron Schacht(Director)
Board seatMisti Ushio· per SEC Form D · $18M raise · filed Jul 2025
Co-investorsAlpha EdisonBaroda VenturesBling CapitalBold Capital PartnersExpansion Venture CapitalMaveron+1 more
BiotechNew York, US
David Pompliano(Executive Officer)David McElligott(Executive Officer, Promoter)
BoardDavid Schubert(Executive Officer, Promoter)Joel Marcus(Director)Lindsay Rayle(Executive Officer, Promoter)Barbara Dalton(Director)
Board seatMisti Ushio· per SEC Form D · $19.9M raise · filed Jan 2017
Co-investorsPfizer Venture Investments
Sunnyvale, US
BoardJohn Chen(Director)Srinivas Rao(Executive Officer, Director)inNobuyuki Kambe(Director)inBernard Lemaitre(Director)
Board seatMisti Ushio· per SEC Form D · $600K raise · filed Jan 2016
Co-investorsPhoenix Venture Partners
Remote patient monitoring software platform utilizing sensors, predictive analytics, and machine learning for real-time personalized care.
HealthtechNew York, US
Eran Ofir(Executive Officer, Director)Charles Herman(Executive Officer, Director)in
BoardMeir Akkerman(Director)Andrew Gianonne(Director)Christopher Geczy(Director)
Board seatDrew TaylorAmit Bansal· per SEC Form D
Co-investorsEast Post Road Ventures
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersNextech InvestOrbiMedVida VenturesNVIDIA
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
Co-investorsCathay HealthMonograph Capital Partners
Avicedar develops glyco-immune checkpoint therapeutics to treat immune-mediated diseases, with an initial focus on Macular Degeneration.
BiotechHealthtech
Co-investorsJeito CapitalLongitude CapitalOrbiMed
B5 Genomics offers the Benthic Analysis Platform, software that converts microarray and sequencing data (short-read and long-read) into high-resolution genotyping and variant calls for complex genomic regions such as HLA, KIR, and the MHC.
AI & Machine LearningBiotechHealthtech
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)inJohn McKearn(Director)in
Co-investorsRiverVest Venture PartnersRoche Venture FundVivo Capital3x5 PartnersCodon Capital
Ansel Health provides health benefit solutions focused on cost-sharing and coverage for unexpected medical bills for employer groups and individuals.
ConsumerHealthtechInsurTechHoboken, US
Amanda Turcotte(Executive Officer)Veer Gidwaney
BoardColin Beire(Director)Elizabeth Bierbower(Director)
Co-investors500 GlobalCity LightFounder CollectiveBrewer Lane VenturesSixThirty Ventures
Candid develops clear aligner technology and offers remote monitoring services for dental professionals to deliver orthodontic treatment.
ConsumerDigital HealthHealthtechMedical Devices
Nick Greenfield(Co-founder & CEO)in
Co-investorsA-Rod CorpAverin CapitalBessemer Venture PartnersBeyond CapitalF-Prime CapitalKube VC+2 more
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)Michael Mendelsohn, M.D.(Founder)in
Co-investorsBain CapitalDelos CapitalNew Enterprise Associates (NEA)
CareDox (operating as SchoolCare) provides a digital health record platform for K-12 school nurse offices that manages immunizations, chronic disease information, and student health compliance reporting.
Digital HealthEdTechHealthtechForest Hills, US
Hesky Kutscher(Executive Officer, Director)
BoardGreg Goff(Director)Eyal Niv(Director)
Co-investorsKima VenturesFirst Round CapitalProlog VenturesTEXO VenturesWestern Technology Investment
Clasp connects employers with healthcare students before graduation and ties student loan repayment to employment, addressing both clinical workforce shortages and student debt.
EdTechFintechHealthtechHR TechBoston, US
Tess Michaels(Founder)in
Co-investorsCrosslink CapitalGSV VenturesJuvo VenturesBlumberg CapitalGradient Ventures
Clasp provides API-based infrastructure and automation for employee health benefits administration, handling quoting, group setup, open enrollment, carrier feeds, and ACA/COBRA compliance.
FintechInsurTechSaaS
Co-investorsTerrainCrosslink Capital
Code Ocean is a cloud computational research platform for reproducible code, data and environments in science.
New York, US
Simon Adar(Executive Officer, Director)
BoardScott Tobin(Director)Joshua Ruch(Director)inMarty Kahn(Director)
Co-investorsBattery VenturesM12 (Microsoft's Venture Fund)Rho Ventures
Eden Brew has developed DeepForte™, a programmable casein micelle platform for nutrient delivery that replicates natural slow-release digestion principles.
BiotechDeep TechFoodTech
Jim Fader(CEO)
Co-investorsBreakthrough VictoriaMain Sequence Ventures
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
BiotechDeep TechSan Carlos, US
Matthew Hill(Executive Officer, Director)in
BoardPeter Zhou(Director)inCain McClary(Director)inJonathan Sheena(Director)
Co-investorsACVC PartnersAndreessen HorowitzRaptor GroupTriatomic CapitalAME Cloud VenturesIn-Q-Tel+1 more
Elemental Machines provides an IoT platform combining hardware, software, and data science to monitor lab and manufacturing equipment, environments, and workflows in real time.
AI & Machine LearningBiotechHardwareHealthtechIoTSaaSCambridge, US
Sridhar Iyengar(Executive Officer, Director)Una Ryan(Director)Jeff Klemens(Director)Sonny Vu(Director)
BoardGaurav Tewari(Director)inRobert Davoli(Director)in
Co-investorsGutbrain VenturesOmega Venture PartnersTau VenturesFounders FundTenOneTen Ventures
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+3 more
Expressable provides online speech therapy delivered by licensed speech therapists for children and adults through live 1-on-1 sessions conducted from home, paired with weekly practice activities and caregiver support.
Digital HealthHealthtechSaaS
Co-investorsNoro-Moseley PartnersSustainVC
Genomics company building a multi-ancestry biobank and AI-driven analytics for clinical genetic testing and drug discovery.
HealthtechMiami Lakes, US
Carlos D. Bustamante(Executive Officer, Director)Arthur Polk(Executive Officer)Alexander Ioannidis(Director)
BoardWale Ayeni(Director)inMohit Kaushal(Director)Nicholas Katsanis(Director)
Co-investorsCEI VenturesCitta CapitalF-Prime CapitalFounder CollectiveFunction VenturesHelios Digital Ventures+2 more
Portfolio company acquired by Roche.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)Mitchell Mutz(Director)Nicholas Walrod(Director)
BoardJohn McKearn(Director)inKarl Handelsman(Director)
Co-investorsRiverVest Venture PartnersRoche Venture Fund
GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.
BiotechDeep TechHealthtechCambridge, US
Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)
BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)
Co-investorsLeaps by BayerREDMILEDreamers VCRising TideAtlas VentureInnovation Endeavors+1 more
Helm Health provides benefit design and member engagement tools for health plans, incorporating cost and quality data into coverage decisions, bundling claims into transparent pricing, and offering provider search functionality.
Enterprise SoftwareHealthtechInsurTechSan Francisco, US
Co-investors.406 Ventures3CC | Third Culture CapitalFlare Capital PartnersHeadwater VenturesSemperVirens Venture CapitalInitialized Capital
Kingdom Supercultures develops functional health ingredients using natural microbes, aiming to improve consumer health.
BiotechFoodTechHealthtechNew MaterialsWellness & Fitness
Co-investors4DX VenturesFour Acres CapitalShine CapitalLux CapitalSALTSupernode Ventures+1 more
Varda industrializes low Earth orbit by manufacturing pharmaceuticals and other specialized products in space, then returning them to Earth via reusable reentry capsules.
BiotechDeep TechSpace TechEl Segundo, US
Will Bruey(Co-founder)inDelian Asparouhov(Co-founder)in
Co-investorsAlso CapitalCaffeinated CapitalFounders FundKhosla VenturesLux CapitalGeneral Catalyst+25 more
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
Cambridge, US
Co-investorsAccess BiotechnologySanofi Ventures
Matchpoint Therapeutics is a drug discovery company developing precision small molecule covalent medicines to treat immune and inflammatory diseases.
AI & Machine LearningBiotechDeep Tech
Andre TurenneJared Cumming(PhD)Christopher HrenThomas Durand-Reville(PhD)Wei Li(MD)Paola Castaldi(PhD)
Co-investorsAtlas VentureSanofi Ventures
Functional nutrition company making supplements for dogs.
St Louis, US
Patrick M Barron(Manager / Member)
Co-investorsCompanion FundR/GA VenturesSelva VenturesCAVU Consumer PartnersCAVU Venture Partners
Neion Bio uses genetic engineering to turn chicken eggs into production systems for recombinant biologic proteins.
Co-investorsCaffeinated CapitalHAWKTAILBasis Set VenturesEnsemble VCHaystackTrust Ventures
Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation.
BiotechHealthtechMedical Devices
Pamela Conley(Founder)in
Co-investorsB Capital GroupB4 CapitalGlobal BioAccess FundMission BiocapitalSanofi VenturesNorwest Venture Partners
Nomina is a unified trading terminal for perpetual future decentralized exchanges (perp DEXs) that lets DeFi users run and automate advanced cross-exchange trading strategies.
Crypto & Web3Data & InfrastructureFintech
Tyler Tarsi(Co-Founder and CTO)Austin King(Founder)in
Co-investorsPantera CapitalCraft VenturesICONIQIW CapitalLever VCRedrice Ventures
Onc.AI develops the Onclara platform, which uses oncology real-world data to build predictive and prognostic AI models for cancer decision-making.
AI & Machine LearningBiotechDigital Health
Co-investorsLifeX VenturesKdT Ventures
Novel antibody-based therapeutics platform for animal health.
Co-investorsCambridge Innovation CapitalCompanion FundParkwalk Advisors
Positive Development provides autism therapy and developmental care services for neurodivergent children and their families.
Digital HealthHealthtechMedical DevicesMental HealthMclean, US
Mike Suiters(Executive Officer, Director)Nick Whitehead(Director)in
BoardAdam Seabrook(Director)inDaniel Gebremedhin(Director)John Banta(Director)Brenton Fargnoli(Director)in
Co-investorsAlleyCorpB Capital GroupB4 CapitalFlare Capital PartnersLifeforce CapitalObvious Ventures+2 more
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthSan Diego, US
Co-investorsDroia VenturesNovartis Venture FundForbionLightspeed Venture PartnersMPM BioImpactVida Ventures+1 more
BiotechHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)XIN JIANG(President & CEO)HANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)EDWARD HURWITZ(Director)
Co-investorsDroia VenturesLightspeed Venture PartnersMPM BioImpactNovartis Venture FundVida VenturesYK Bioventures
Reema Health provides behavioral health services combined with social needs navigation, using community care workers and a virtual care team to help members address unmet social needs such as food insecurity, housing, transportation, and loneliness.
Digital HealthHealthtechMental HealthMinneapolis, US
Matthew Swanson(Director)Amon Anderson(Director)Justin Ley(Executive Officer, Director)
BoardHelen Ciesielski(Director)Ellen Herlacher(Director)Mike Cunningham(Director)
Co-investorsGROOVE CAPITALHC9 VenturesHeadwater VenturesLRVHealthMaC Venture CapitalMatchstick Ventures+2 more
Rejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer.
BiotechHealthtechLongevitySan Diego, US
Noah Davidsohn(CSO, Co-Founder)Daniel Oliver(CEO, Co-Founder)George Church(Co-Founder and SAB)Deborah Ascheim(Chief Medical Officer)
Co-investorsCompanion FundConnecticut InnovationsKendall Capital PartnersKdT Ventures
Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals.
AgTechBiotechDeep TechHealthtechPhiladelphia, US
Mark Hefferman(Executive Officer, Director)
BoardAditya Kohli(Director)inTadataka Yamada(Director)Patrick Heron(Director)inCindy Cole(Director)inNancy Hong(Director)
Co-investorsCompanion FundFrazier Life SciencesRiverVest Venture Partners
Scratch Pay offers point-of-payment patient financing that lets clients of veterinary practices apply for loans and receive instant decisions, with practices paid up front via ACH.
ConsumerFintechHealthtechLos Angeles, US
John(Founder/CEO)Caleb(Founder/President)John Keatley(Founder)
Co-investorsArgonautic VenturesCompanion FundNorwest Venture PartnersStruck CapitalSWS Venture CapitalTTV Capital
Co-investorsLifeforce CapitalPfizer Venture Investments
BiotechWaltham, US
Ellen E. Sheets(Executive Officer, Director)
BoardCarl M. Berke(Director)Nancy Hong(Director)
Co-investorsBold Capital PartnersRiverVest Venture PartnersKdT Ventures
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Si-Ping Han(Secretary)Deepshikha Datta(Chief Executive Officer and President)
BoardKevin Zhang(Director)Alicia Irurzun-Lafitte(Director)inDylan Morris(Director)
Co-investorsBold Capital PartnersCRV (Charles River Ventures)FREEFLOWGlobal BrainOno Venture Investment, Inc.Upfront Ventures+2 more
T-Therapeutics develops bispecific TCR-CD3 T cell engagers built on its OpTiMus TCR discovery platform to target previously undruggable intracellular targets.
BiotechDeep TechHealthtechCambridge, GB
Co-investorsF-Prime CapitalSanofi VenturesSofinnova PartnersCambridge Innovation Capital
Terray is a drug discovery company that combines proprietary hardware, large-scale experimental datasets, and AI through its EMMI platform to design small molecule medicines.
AI & Machine LearningBiotechDeep Tech
Eli Berlin(Founder)in
BoardChris PicardoinDusan PerovicSid ShenaiinSamuel BjorkinBassil Dahiyat, Ph.D.
Co-investorsDeviation CapitalMadrona Venture GroupSummit Peak InvestmentsKdT VenturesMana VenturesNVentures+1 more
Transcera is a biotech company developing a new class of therapeutics that use natural lipid trafficking pathways to direct extracellular proteins into lysosomes for degradation, targeting soluble and membrane proteins to treat chronic diseases.
BiotechDeep TechBoston, US
Co-investorsTau Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioFaeth TherapeuticsNASDAQ: FTHGood Therapeuticsacq. by RocheScout Bio Incacq. by Ceva Santé Animale
Portfolio news
latest coverage across their companies
Rejuvenate Bio · intelligence360.news · Jul 30, 2026
Clasp · fortuneindia.com · Jul 17, 2026
Alterome Therapeutics, Inc. · geekwire.com · Jul 13, 2026
Omni · businesswire.com · Jul 6, 2026
Neion Bio · allsci.com · Jun 12, 2026
Protego · finsmes.com · Apr 23, 2026
Clasp · forbes.com · Apr 3, 2026
Elemental Machines · trysignalbase.com · Mar 25, 2026
Frequently asked questions
- How many investments has Digitalis Ventures made?
- Digitalis Ventures has 19 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does Digitalis Ventures invest at?
- Digitalis Ventures invests at the Seed, Series A, Late Stage stages.
- What is Digitalis Ventures's typical check size?
- Digitalis Ventures typically writes checks of $100K – $10M.
- What sectors does Digitalis Ventures focus on?
- Digitalis Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Digitalis Ventures located?
- Digitalis Ventures is headquartered in New York, US.
- Does Digitalis Ventures lead rounds?
- Yes, Digitalis Ventures leads investment rounds.
- Who does Digitalis Ventures co-invest with?
- Digitalis Ventures most often shares deals with Companion Fund, RiverVest Venture Partners, Battery Ventures, among 31 tracked co-investors.
Images
Co-investors · 29
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Bold Capital Partners is a venture capital firm based in Los Angeles, California. Its portfolio includes companies such as Insilico Medicine, which applies artificial intelligence to biomarker development and drug discovery, reflecting a focus on frontier technologies in areas like AI-driven life sciences.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
Founder Collective is a seed and pre-seed stage venture capital firm that invests across sectors, describing itself as sector agnostic and anti-thematic.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Cambridge Innovation Capital (CIC) is a UK-based venture capital firm backing entrepreneurs in life sciences and deep tech, leveraging its position in the Cambridge science and technology ecosystem.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Innovation Endeavors is an early-stage venture fund that invests in founders and supports venture creation through pre-team and pre-idea programs. The firm provides portfolio companies with access to mentors, advisors, and an entrepreneur ecosystem.
Madrona Venture Group is a Seattle-founded venture firm that partners with founders across early and acceleration stages, providing capital plus hands-on support in recruiting, strategy, business development, and fundraising.
▶17 more co-investors
Polaris PartnersGutbrain VenturesSofinnova PartnersConnecticut InnovationsParkwalk AdvisorsCodon CapitalOmega Venture PartnersTechstarsPICUS CAPITALDN CapitalTwo Sigma VenturesWhat If VenturesArtis Ventures7wire VenturesAccess IndustriesQiming Venture PartnersSageview Capital
Firms observed investing alongside Digitalis Ventures, from public investor directories. Shared companies are the overlap with Digitalis Ventures's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.